{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T21:05:13Z","timestamp":1784322313215,"version":"3.55.0"},"reference-count":159,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.pathol.2026.03.014","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:39:16Z","timestamp":1779925156000},"page":"507-524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent advances in the understanding of TP53 in haematological malignancies"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7995-4696","authenticated-orcid":false,"given":"Jun Yen","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti","family":"Talaulikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2026.03.014_bib1","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1128\/jvi.31.2.472-483.1979","article-title":"Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum","volume":"31","author":"Kress","year":"1979","journal-title":"J Virol"},{"key":"10.1016\/j.pathol.2026.03.014_bib2","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1128\/MCB.15.8.4489","article-title":"Identification of a novel p53 promoter element involved in genotoxic stress-inducible p53 gene expression","volume":"15","author":"Sun","year":"1995","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pathol.2026.03.014_bib3","first-page":"6264","article-title":"Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status","volume":"14","author":"Graeber","year":"1994","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pathol.2026.03.014_bib4","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in cancer: from molecular mechanism to therapeutic modulation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.pathol.2026.03.014_bib5","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1073\/pnas.052713099","article-title":"Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function","volume":"99","author":"de Vries","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pathol.2026.03.014_bib6","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/humu.22552","article-title":"TP53 Mutations in human cancer: database reassessment and prospects for the next decade","volume":"35","author":"Leroy","year":"2014","journal-title":"Hum Mutat"},{"issue":"Suppl 1","key":"10.1016\/j.pathol.2026.03.014_bib7","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1182\/blood-2024-210051","article-title":"Spectrum of TP53 mutation in hematologic malignancies","volume":"144","author":"Jang","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib8","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1073\/pnas.88.12.5413","article-title":"p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia","volume":"88","author":"Gaidano","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pathol.2026.03.014_bib9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1073\/pnas.83.1.130","article-title":"The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13)","volume":"83","author":"McBride","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pathol.2026.03.014_bib10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/sj.onc.1201244","article-title":"Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity","volume":"15","author":"Candau","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.pathol.2026.03.014_bib11","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1073\/pnas.0811023106","article-title":"Cooperative regulation of p53 by modulation of ternary complex formation with CBP\/p300 and HDM2","volume":"106","author":"Ferreon","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pathol.2026.03.014_bib12","doi-asserted-by":"crossref","first-page":"15335","DOI":"10.1073\/pnas.93.26.15335","article-title":"Identification of a novel p53 functional domain that is necessary for efficient growth suppression","volume":"93","author":"Walker","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pathol.2026.03.014_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/nar\/26.1.205","article-title":"IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools","volume":"26","author":"Hainaut","year":"1998","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.pathol.2026.03.014_bib14","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1101\/gad.7.12b.2556","article-title":"The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots","volume":"7","author":"Pavletich","year":"1993","journal-title":"Genes Dev"},{"key":"10.1016\/j.pathol.2026.03.014_bib15","first-page":"5182","article-title":"p53 Domains: structure, oligomerization, and transformation","volume":"14","author":"Wang","year":"1994","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pathol.2026.03.014_bib16","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/0092-8674(92)90562-Q","article-title":"Regulation of the specific DNA binding function of p53","volume":"71","author":"Hupp","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.pathol.2026.03.014_bib17","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1073\/pnas.96.5.2147","article-title":"p53 regulates a G2 checkpoint through cyclin B1","volume":"96","author":"Innocente","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pathol.2026.03.014_bib18","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1097-2765(01)00214-3","article-title":"PUMA, a novel proapoptotic gene, is induced by p53","volume":"7","author":"Nakano","year":"2001","journal-title":"Mol Cell"},{"key":"10.1016\/j.pathol.2026.03.014_bib19","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1074\/jbc.M112.422204","article-title":"Direct interaction of Bax and Bak proteins with Bcl-2 homology Domain 3 (BH3)-only proteins in living cells revealed by fluorescence complementation","volume":"288","author":"Vela","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pathol.2026.03.014_bib20","first-page":"4638","article-title":"p53 Promotes selection for fas-mediated apoptotic resistance1","volume":"60","author":"Maecker","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.pathol.2026.03.014_bib21","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/sj.onc.1203489","article-title":"Wild-type p53 transactivates the KILLER\/DR5 gene through an intronic sequence-specific DNA-binding site","volume":"19","author":"Takimoto","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.pathol.2026.03.014_bib22","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1128\/MCB.22.10.3497-3508.2002","article-title":"Oncogenic ras and p53 cooperate to induce cellular senescence","volume":"22","author":"Ferbeyre","year":"2002","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pathol.2026.03.014_bib23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0092-8674(00)81902-9","article-title":"Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a","volume":"88","author":"Serrano","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.pathol.2026.03.014_bib24","doi-asserted-by":"crossref","first-page":"28073","DOI":"10.1074\/jbc.272.44.28073","article-title":"Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts","volume":"272","author":"Ford","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pathol.2026.03.014_bib25","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/emboj\/20.4.914","article-title":"A role for p53 in base excision repair","volume":"20","author":"Zhou","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.pathol.2026.03.014_bib26","first-page":"1508","article-title":"p53 Modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of Cisplatin1","volume":"61","author":"Lin","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.pathol.2026.03.014_bib27","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1002\/j.1460-2075.1996.tb00919.x","article-title":"MDMX: a novel p53-binding protein with some functional properties of MDM2","volume":"15","author":"Shvarts","year":"1996","journal-title":"EMBO J"},{"key":"10.1016\/j.pathol.2026.03.014_bib28","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/0092-8674(92)90644-R","article-title":"The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation","volume":"69","author":"Momand","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.pathol.2026.03.014_bib29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0014-5793(97)01480-4","article-title":"Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53","volume":"420","author":"Honda","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pathol.2026.03.014_bib30","first-page":"6304","article-title":"Participation of p53 protein in the cellular response to DNA damage","volume":"51","author":"Kastan","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.pathol.2026.03.014_bib31","first-page":"6264","article-title":"Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status","volume":"14","author":"Graeber","year":"1994","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pathol.2026.03.014_bib32","doi-asserted-by":"crossref","first-page":"36194","DOI":"10.1074\/jbc.M104157200","article-title":"Reactive oxygen species-induced phosphorylation of p53 on Serine 20 is mediated in part by polo-like Kinase-3","volume":"276","author":"Xie","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pathol.2026.03.014_bib33","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.cmet.2018.07.005","article-title":"A role for p53 in the adaptation to glutamine starvation through the expression of SLC1A3","volume":"28","author":"Tajan","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.pathol.2026.03.014_bib34","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0092-8674(00)81902-9","article-title":"Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a","volume":"88","author":"Serrano","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.pathol.2026.03.014_bib35","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/ajh.27650","article-title":"TP53 mutations detected by NGS are a major clinical risk factor for stratifying mantle cell lymphoma","volume":"100","author":"Lazarian","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2026.03.014_bib36","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.pathol.2026.03.014_bib37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-023-01480-y","article-title":"Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia","volume":"16","author":"Bahaj","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.pathol.2026.03.014_bib38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41408-023-00821-x","article-title":"TP53 mutation variant allele frequency of \u226510% is associated with poor prognosis in therapy-related myeloid neoplasms","volume":"13","author":"Shah","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2026.03.014_bib39","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0140-6736(03)12856-5","article-title":"Prediction of pathogenic mutations in patients with early-onset breast cancer by family history","volume":"361","author":"Lalloo","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2026.03.014_bib40","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1200\/JCO.2008.16.6959","article-title":"Beyond Li-Fraumeni syndrome: clinical characteristics of families with p53 germline mutations","volume":"27","author":"Gonzalez","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pathol.2026.03.014_bib41","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.10613","article-title":"Hematologic malignancies in Li-Fraumeni syndrome","volume":"42","author":"Donovan","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pathol.2026.03.014_bib42","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1002\/cncr.31331","article-title":"Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels","volume":"124","author":"DiNardo","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2026.03.014_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_432218","article-title":"Germline predisposition in hematologic malignancies: testing, management, and implications","volume":"44","author":"Godley","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.pathol.2026.03.014_bib44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/jmedgenet-2017-104976","article-title":"Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome","volume":"55","author":"Renaux-Petel","year":"2018","journal-title":"J Med Gen"},{"key":"10.1016\/j.pathol.2026.03.014_bib45","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2026.03.014_bib46","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood.V85.8.2189.bloodjournal8582189","article-title":"TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities","volume":"85","author":"Kaneko","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib47","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pathol.2026.03.014_bib48","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1038\/s41467-019-13542-2","article-title":"Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway","volume":"10","author":"Chen","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.pathol.2026.03.014_bib49","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2023-186454","article-title":"Age-specific induction of mutant p53 drives clonal hematopoiesis in adult mice leading to acute myeloid leukemia","volume":"142","author":"Pourebrahim","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib50","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41408-025-01350-5","article-title":"Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults","volume":"15","author":"Harris","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2026.03.014_bib51","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/2643-3230.BCD-22-0154","article-title":"Adult low-hypodiploid acute lymphoblastic leukemia emerges from preleukemic TP53-mutant clonal hematopoiesis","volume":"4","author":"Kim","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.pathol.2026.03.014_bib52","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/ng.2532","article-title":"The genomic landscape of hypodiploid acute lymphoblastic leukemia","volume":"45","author":"Holmfeldt","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2026.03.014_bib53","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.pathol.2026.03.014_bib54","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41588-023-01472-1","article-title":"Multiparameter prediction of myeloid neoplasia risk","volume":"55","author":"Gu","year":"2023","journal-title":"Nat Gen"},{"key":"10.1016\/j.pathol.2026.03.014_bib55","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s44161-022-00206-6","article-title":"TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease","volume":"2","author":"Zekavat","year":"2023","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.pathol.2026.03.014_bib56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2024-205209","article-title":"The pathogenesis of therapy-related myeloid neoplasms from tp53-mutant clonal hematopoiesis","volume":"144","author":"Fullin","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib57","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2025-4","article-title":"CDK4\/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis","volume":"146","author":"Chan","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35950","article-title":"Early identification of TP53 mutations and TP53 allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point-of-care p53 immunohistochemistry","volume":"131","author":"Patel","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2026.03.014_bib59","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.pathol.2024.11.011","article-title":"p53 immunohistochemistry staining is a rapid screening method for TP53 mutation in myeloid malignancies suitable for integration into routine diagnostic laboratory practice","volume":"57","author":"Nelles","year":"2025","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2026.03.014_bib60","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.pathol.2023.11.009","article-title":"Immunohistochemistry screening for TP53 mutation in myeloid neoplasms in AZF-fixed bone marrow biopsies","volume":"56","author":"Yang","year":"2024","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2026.03.014_bib61","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2023020855","article-title":"TP53 status and impact on AML prognosis within the ELN 2022 risk classification","volume":"142","author":"Fleming","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib62","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pathol.2026.03.014_bib63","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2026.03.014_bib64","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/leu.2016.263","article-title":"The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases","volume":"31","author":"Stengel","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2026.03.014_bib65","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/bloodadvances.2024015238","article-title":"Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations","volume":"9","author":"Shah","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2026.03.014_bib66","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1182\/blood-2019-132014","article-title":"Landscape of TP53 mutations in MPN","volume":"134","author":"Farnoud","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib67","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ajh.27609","article-title":"TP53 mutations in myeloproliferative neoplasms: context-dependent evaluation of prognostic relevance","volume":"100","author":"Tefferi","year":"2025","journal-title":"Am J Hem"},{"key":"10.1016\/j.pathol.2026.03.014_bib68","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1182\/bloodadvances.2023010156","article-title":"Genomic landscape of TP53-mutated myeloid malignancies","volume":"7","author":"Abel","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2026.03.014_bib69","first-page":"1304","article-title":"Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms","volume":"110","author":"Senapati","year":"2025","journal-title":"Haematology"},{"key":"10.1016\/j.pathol.2026.03.014_bib70","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","article-title":"TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","volume":"33","author":"Haase","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2026.03.014_bib71","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41408-024-01077-9","article-title":"Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms","volume":"14","author":"Kaur","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2026.03.014_bib72","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.2020006158","article-title":"TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib73","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","article-title":"TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML","volume":"4","author":"Vadakekolathu","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2026.03.014_bib74","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41588-023-01480-1","article-title":"Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution","volume":"55","author":"Rodriguez-Meira","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2026.03.014_bib75","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/ajh.27655","article-title":"TP53-mutated myeloid neoplasms: 2024 update on diagnosis, risk-stratification, and management","volume":"100","author":"Shah","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2026.03.014_bib76","volume":"11","year":"2024"},{"key":"10.1016\/j.pathol.2026.03.014_bib77","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib78","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/bloodadvances.2024014140","article-title":"Diagnosis of TP53-mutated myeloid disease by the ICC and WHO fifth edition classifications","volume":"9","author":"Hart","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2026.03.014_bib79","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib80","first-page":"3533","article-title":"Prognostic impact of \u2018multi-hit\u2019 versus \u2018single-hit\u2019 TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases","volume":"109","author":"Badar","year":"2024","journal-title":"Haematology"},{"key":"10.1016\/j.pathol.2026.03.014_bib81","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/ajh.27670","article-title":"Multihit TP53 mutations in myeloproliferative neoplasms and acute myeloid leukemia: comparative analysis of survival and risk factors in 142 informative cases","volume":"100","author":"Fathima","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2026.03.014_bib82","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib83","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.pathol.2026.03.014_bib84","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2026.03.014_bib85","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pathol.2026.03.014_bib86","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2026.03.014_bib87","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/blood-2024-209416","article-title":"p53 Immunohistochemistry as a high-specificity biomarker to predict allelic state and overall survival in myelodysplastic syndrome or acute myeloid leukemia with mutated TP53","volume":"144","author":"Patel","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib88","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1182\/blood.V126.23.5228.5228","article-title":"Mechanisms of resistance to Lenalidomide in del(5q) myelodysplastic syndrome patients","volume":"126","author":"Martinez-H\u00f8yer","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib89","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2024-211997","article-title":"Failure to execute caspase activation drives therapy resistance in TP53 mutated AML","volume":"144","author":"Mamdouh","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib90","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood-2023-185059","article-title":"The mevalonate pathway is a therapeutic target in TP53 mutant acute myeloid leukemia","volume":"142","author":"Skuli","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib91","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to bcl2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pathol.2026.03.014_bib92","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.2024027408","article-title":"Magrolimab plus azacitidine vs physician\u2019s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study","volume":"146","author":"Zeidner","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib93","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2021-154151","article-title":"Non-relapse mortality in TP53-mutated MDS\/AML - a multi-center collaborative study","volume":"138","author":"Byrne","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib94","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/bloodadvances.2020003508","article-title":"Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes","volume":"5","author":"Hunter","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2026.03.014_bib95","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1182\/bloodadvances.2023011384","article-title":"TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era","volume":"7","author":"Landsburg","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2026.03.014_bib96","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1182\/blood-2021-149899","article-title":"Comprehensive analysis of TP53 mutation characteristics and identification of patients with inferior prognosis and enhanced immune escape in diffuse large B cell lymphoma","volume":"138","author":"Zhang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib97","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood-2009-05-224071","article-title":"Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial","volume":"114","author":"Zenz","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00610-y","article-title":"Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma","volume":"12","author":"Martello","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2026.03.014_bib99","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood-2011-11-366062","article-title":"Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies","volume":"119","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.2010.1919","article-title":"Association of a MicroRNA\/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia","volume":"305","author":"Fabbri","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.pathol.2026.03.014_bib101","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pathol.2021.04.008","article-title":"Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax","volume":"54","author":"G\u00e1ng\u00f3","year":"2022","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2026.03.014_bib102","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood.2020008276","article-title":"B-cell receptor signaling and genetic lesions in TP53 and CDKN2A\/CDKN2B cooperate in Richter transformation","volume":"138","author":"Chakraborty","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib103","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.21.02143","article-title":"Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy","volume":"40","author":"Shouval","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pathol.2026.03.014_bib104","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2007-02-072082","article-title":"Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma","volume":"110","author":"Young","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib105","article-title":"The landscape of TP53 mutations and their prognostic impact in chronic lymphocytic leukemia","volume":"8","author":"Bertossi","year":"2024","journal-title":"Hemasphere"},{"key":"10.1016\/j.pathol.2026.03.014_bib106","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2014-02-558833","article-title":"TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis","volume":"124","author":"Stengel","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib107","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.2020008346","article-title":"del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib108","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/ajh.26507","article-title":"Expression of p53 protein isoforms predicts survival in patients with multiple myeloma","volume":"97","author":"Rojas","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2026.03.014_bib109","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-023-01977-y","article-title":"Clinical outcome of mantle cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)","volume":"37","author":"Scheubeck","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2026.03.014_bib110","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/bjh.17023","article-title":"p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma","volume":"191","author":"Rodrigues","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2026.03.014_bib111","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/modpathol.2016.178","article-title":"P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC\/BCL2 expression in diffuse large B-cell lymphoma","volume":"30","author":"Wang","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2026.03.014_bib112","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1309\/AJCPHC85DGAXZDBE","article-title":"p53 nuclear expression correlates with hemizygous tp53 deletion and predicts an adverse outcome for patients with relapsed\/refractory multiple myeloma treated with lenalidomide","volume":"137","author":"Chen","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.pathol.2026.03.014_bib113","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","article-title":"High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma","volume":"133","author":"Thakurta","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib114","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1182\/bloodadvances.2022009040","article-title":"Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL","volume":"7","author":"Griffin","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2026.03.014_bib115","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1078-0432.CCR-08-1630","article-title":"The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2026.03.014_bib116","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2011.162","article-title":"Impact of TP53 mutation and 17p deletion in mantle cell lymphoma","volume":"25","author":"Halld\u00f3rsd\u00f3ttir","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2026.03.014_bib117","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib118","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.2020009530","article-title":"Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options","volume":"138","author":"Malcikova","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib119","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/s41375-024-02267-x","article-title":"ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia\u20142024 update","volume":"38","author":"Malcikova","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2026.03.014_bib120","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/imj.16561","article-title":"Diagnosis and management of mantle cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance","volume":"55","author":"Barraclough","year":"2025","journal-title":"Int Med J"},{"key":"10.1016\/j.pathol.2026.03.014_bib121","author":"Quach"},{"key":"10.1016\/j.pathol.2026.03.014_bib122","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2026.03.014_bib123","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pathol.2026.03.014_bib124","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/bloodadvances.2024014986","article-title":"TP53 mutations are associated with CD19\u2212relapse and inferior outcomes after blinatumomab in adults with ALL","volume":"9","author":"Aldoss","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2026.03.014_bib125","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1182\/blood.2019004492","article-title":"Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax","volume":"135","author":"Tausch","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib126","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1158\/1078-0432.CCR-20-4890","article-title":"Clinical outcomes in patients with multi-hit TP53 chronic lymphocytic leukemia treated with Ibrutinib","volume":"27","author":"Brieghel","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2026.03.014_bib127","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.1182\/blood-2025-5669","volume":"146","author":"Shadman","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib128","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib129","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1182\/bloodadvances.2023011152","article-title":"Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study","volume":"8","author":"Tivey","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2026.03.014_bib130","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/bloodadvances.2022008916","article-title":"A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma","volume":"7","author":"Sawalha","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2026.03.014_bib131","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pathol.2026.03.014_bib132","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.2024025563","article-title":"Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation","volume":"145","author":"Kumar","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib133","author":"Bing"},{"key":"10.1016\/j.pathol.2026.03.014_bib134","author":"Sun"},{"key":"10.1016\/j.pathol.2026.03.014_bib135","author":"Zhang"},{"key":"10.1016\/j.pathol.2026.03.014_bib137","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.pathol.2026.03.014_bib138","doi-asserted-by":"crossref","first-page":"10786","DOI":"10.1074\/jbc.M109.056747","article-title":"Identification and characterization of the first small molecule inhibitor of MDMX","volume":"285","author":"Reed","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pathol.2026.03.014_bib139","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm0302-282","article-title":"Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound","volume":"8","author":"Bykov","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.pathol.2026.03.014_bib140","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2141.1994.tb05044.x","article-title":"Over-expression of the MDM2 gene is found in some cases of haematological malignancies","volume":"88","author":"Quesnel","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2026.03.014_bib141","first-page":"4147","article-title":"Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial","volume":"6","author":"Konopleva","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2026.03.014_bib142","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1182\/blood.2023020731","article-title":"The role of the MDM2\/p53 axis in antitumor immune responses","volume":"143","author":"Brummer","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib143","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1073\/pnas.1620262114","article-title":"Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf\u2212\/\u2212 mouse model","volume":"114","author":"Chapeau","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pathol.2026.03.014_bib144","first-page":"1","article-title":"MDM2 inhibition is associated with the emergence of TP53-altered clonal hematopoiesis","volume":"9","author":"Khanna","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.pathol.2026.03.014_bib152","doi-asserted-by":"crossref","first-page":"eabc8697","DOI":"10.1126\/science.abc8697","article-title":"Targeting a neoantigen derived from a common TP53 mutation","volume":"371","author":"Hsiue","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.pathol.2026.03.014_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217421","article-title":"Vaccines targeting p53 mutants elicit anti-tumor immunity","volume":"611","author":"Chai","year":"2025","journal-title":"Cancer Lett"},{"key":"10.1016\/j.pathol.2026.03.014_bib155","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ccr.2009.03.003","article-title":"PRIMA-1 reactivates mutant p53 by covalent binding to the core domain","volume":"15","author":"Lambert","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pathol.2026.03.014_bib156","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pathol.2026.03.014_bib158","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(22)00403-3","article-title":"Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study","volume":"10","author":"Garcia-Manero","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.pathol.2026.03.014_bib159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-021-03988-y","article-title":"Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells","volume":"12","author":"Ceder","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.pathol.2026.03.014_bib160","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3324\/haematol.2018.199364","article-title":"Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia","volume":"105","author":"Demir","year":"2020","journal-title":"Haematology"},{"key":"10.1016\/j.pathol.2026.03.014_bib161","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/91.9.763","article-title":"Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer","volume":"91","author":"Swisher","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.pathol.2026.03.014_bib162","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41571-023-00842-2","article-title":"Pharmacological reactivation of p53 in the era of precision anticancer medicine","volume":"21","author":"Tuval","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pathol.2026.03.014_bib164","doi-asserted-by":"crossref","first-page":"TPS3165","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS3165","article-title":"A window of opportunity trial of atorvastatin in p53-mutant and p53 wild type malignancies","volume":"37","author":"Telfah","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pathol.2026.03.014_bib165","first-page":"3551","article-title":"Database of p53 gene somatic mutations in human tumors and cell lines","volume":"22","author":"Hollstein","year":"1994","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.pathol.2026.03.014_bib166","series-title":"Cancer targeting therapies for the p53","author":"Silva","year":"2026"},{"key":"10.1016\/j.pathol.2026.03.014_bib167","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2026.03.014_bib168","series-title":"World Health Organization classification of tumours of haematopoietic and lymphoid tissues","year":"2017"},{"key":"10.1016\/j.pathol.2026.03.014_bib169","author":"Baranda"},{"key":"10.1016\/j.pathol.2026.03.014_bib171","author":"Li"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302526005209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302526005209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T20:34:47Z","timestamp":1784320487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302526005209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":159,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0031302526005209"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2026.03.014","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the understanding of TP53 in haematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2026.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of Royal College of Pathologists of Australasia.","name":"copyright","label":"Copyright"}]}}